Telesis Bio, Inc. (TBIO)

Market Cap	18.02K -16.7%
Revenue (ttm)	17.03M -32.5%
Net Income	-47.93M
EPS	-28.02
Shares Out	1.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,325
Open	0.0100
Previous Close	0.0110
Day's Range	0.0100 - 0.0100
52-Week Range	0.0001 - 0.1500
Beta	-13.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error